natgillin/translations-raw huggingface dataset:
Simponi is available as pre-filled pens and syringes containing a solution for injection under the skin. 
Zdravilo Simponi je na voljo v obliki napolnjenih injekcijskih peresnikov in brizg, ki vsebujejo raztopino za injiciranje pod kožo.
The active substance in Simponi, golimumab, is a monoclonal antibody. 
Učinkovina v zdravilu Simponi, golimumab, je monoklonsko protitelo.
Simponi is used in combination with methotrexate. 
Zdravilo Simponi se uporablja v kombinaciji z metotreksatom.
Data from X-rays taken before and after two years of treatment showed less joint damage in patients receiving Simponi than in those receiving placebo. 
Podatki, pridobljeni z rentgenskim slikanjem pred zdravljenjem in dve leti po njem, so pokazali manj poškodb sklepov pri bolnikih, ki so jemali zdravilo Simponi, kot pri tistih, ki so prejemali placebo.
The recommended dose depends on the disease Simponi is used to treat and the response of the patient. 
Priporočeni odmerek je odvisen od bolezni, za zdravljenje katere se zdravilo Simponi uporablja, in bolnikovega odziva.
Patients should show this card when seeing a healthcare professional, so that they are aware that the patient is using Simponi. 
To kartico morajo pokazati zdravstvenemu delavcu in ga s tem seznanijo, da bolnik uporablja zdravilo Simponi.
Golimumab has been designed to attach to and block a substance in the body called tumour necrosis factor alpha (TNF-α). 
Golimumab je bil zasnovan tako, da se v telesu veže na snov, imenovano tumorje nekrozitirajoči faktoralfa (TNF-), in jo zavira.
Simponi can only be obtained with a prescription and treatment must be initiated and supervised by a qualified doctor who has experience in the diagnosis and treatment of the diseases that Simponi is used to treat. 
Predpisovanje in izdaja zdravila Simponi je le na recept, zdravljenje z njim pa lahko uvede in nadzoruje le zdravnik specialist, ki ima izkušnje z diagnosticiranjem in zdravljenjem bolezni, za katere se zdravilo Simponi uporablja.
Of these patients, 87% of (151 out of 173) had 30% reduction in the number and severity of symptoms after 16 weeks. 
Pri 87 % (151 od 173) od teh bolnikov je po 16 tednih prišlo do 30-odstotnega zmanjšanja števila in resnosti simptomov.
This substance is involved in causing inflammation and is found at high levels in patients with the diseases that Simponi is used to treat. 
Ta snov sodeluje pri nastanku vnetij in je v visokih koncentracijah prisotna pri bolnikih z boleznimi, za zdravljenje katerih se uporablja zdravilo Simponi.
Simponi is an anti-inflammatory medicine. 
Zdravilo Simponi je protivnetno zdravilo.
The first study, involving 1,065 patients, compared different doses of Simponi with placebo as induction treatment. 
V prvi študiji, v katero je bilo vključenih 1 065 bolnikov, so primerjali različne odmerke zdravila Simponi s placebom kot uvodnim zdravljenjem.
For non-radiographic axial spondyloarthritis, Simponi was compared with placebo over 16 weeks in one main study involving 198 patients who had the disease without evidence of ankylosing spondylitis but with signs of inflammation and who had not responded adequately to treatment with NSAIDs. 
Pri neradiografskem aksialnem spondiloartritisu so zdravilo Simponi 16 tednov primerjali s placebom v eni glavni študiji, v katero je bilo vključenih 198 bolnikov, katerih bolezen je bila brez znakov ankilozirajočega spondilitisa, toda z znaki vnetja, in pri katerih je bil odziv na zdravljenje z NSAID nezadosten.
• polyarticular juvenile idiopathic arthritis (a rare childhood disease causing inflammation of many joints). 
• določenih oblik juvenilnega idiopatskega artritisa (redke otroške bolezni, ki povzroča vnetje več sklepov).
• active and progressive psoriatic arthritis (a disease causing red, scaly patches on the skin and inflammation of the joints). 
• aktivnega in napredovalega psoriatičnega artritisa (bolezni, ki povzroča nastajanje rdečih in luskinastih zaplat na koži in vnetje sklepov).
How is Simponi used? 
Kako se zdravilo Simponi uporablja?
How does Simponi work? 
Kako zdravilo Simponi deluje?
After training, patients may inject themselves with Simponi if their doctor agrees. 
Ob soglasju zdravnika si lahko bolniki po opravljenem usposabljanju zdravilo Simponi vbrizgavajo sami.
The second study, involving 1,228 patients, compared Simponi 50 or 100 mg with placebo as maintenance treatment. 
V drugi študiji, v katero je bilo vključenih 1 228 bolnikov, so 50- ali 100-miligramske odmerke zdravila Simponi primerjali s placebom kot vzdrževalnim zdravljenjem.
Simponi is used in adults who have not responded adequately to other treatments. 
Zdravilo Simponi se uporablja pri odraslih, pri katerih je bil odziv na druga zdravljenja neustrezen.
• axial spondyloarthritis (a disease causing inflammation and pain in the joints of the spine), including: - adults with severe active ankylosing spondylitis who have not responded adequately to other treatments; - adults with severe non-radiographic axial spondyloarthritis (when there are objective signs of inflammation but no abnormalities seen on x-ray) who have not responded adequately or are intolerant to anti-inflammatory medicines called non-steroidal anti-inflammatory drugs (NSAIDs); 
- odraslih s hudim neradiografskim aksialnim spondiloartritisom (kadar so vidni znaki vnetja, a rentgensko slikanje ni pokazalo nepravilnosti), ki se niso zadovoljivo odzvali na protivnetna zdravila, imenovana nesteroidna protivnetna zdravila (NSAID), ali jih ne prenašajo;
• moderately to severely active ulcerative colitis (a disease causing inflammation and ulcers in the lining of the gut). 
• zmernega do hudega aktivnega ulceroznega kolitisa (bolezni, ki povzroča vnetje in pojavljanje razjed v črevesni sluznici).
Simponi is used in adults who have not responded adequately to, or cannot use, conventional treatment; 
Zdravilo Simponi se uporablja pri odraslih bolnikih, pri katerih je bil odziv na običajno zdravljenje neustrezen ali pri katerih se običajno zdravljenje ne more uporabiti;
For rheumatoid arthritis, Simponi was compared with placebo (a dummy treatment) in three studies involving 1,542 patients with moderate to severe rheumatoid arthritis, including patients who had not received or responded adequately to other treatments. 
Pri revmatoidnem artritisu so zdravilo Simponi primerjali s placebom (zdravilom brez učinkovine) v treh študijah, v katere je bilo vključenih 1 542 bolnikov z zmernim do hudim revmatoidnim artritisom, vključno z bolniki, pri katerih je bil odziv na druga zdravljenja neustrezen ali ga niso prejeli.
• active rheumatoid arthritis (a disease causing inflammation of the joints). 
• aktivnega revmatoidnega artritisa (bolezni, ki povzroča vnetje sklepov).
For the full list of restrictions with Simponi, see the package leaflet. 
Za celoten seznam omejitev pri uporabi zdravila Simponi glejte navodilo za uporabo.
In the first study, in which patients were also given methotrexate, after 14 weeks, 55% patients who received Simponi (49 out of 89) achieved 20% reductions compared with 33% (44 out of 133) of patients who received placebo. 
V prvi študiji, v kateri so bolniki prejeli tudi metotreksat, je po 14 tednih prišlo do 20-odstotnega zmanjšanja simptomov pri 55 % (49 od 89) bolnikov, ki so prejemali zdravilo Simponi, v primerjavi s 33 % (44 od 133) bolnikov, ki so prejemali placebo.
In the first study, around 51% of patients receiving induction treatment with Simponi (starting at 200 mg) responded to treatment after 6 weeks, compared with around 30% of patients given placebo. 
V prvi študiji se je po šestih tednih na zdravljenje odzvalo približno 51 % bolnikov, ki so prejemali uvodno zdravljenje z zdravilom Simponi (z začetnim 6odmerkom 200 mg), v primerjavi z okrog 30 % bolnikov, ki so prejemali placebo.
Simponi contains the active substance golimumab. 
Zdravilo Simponi vsebuje učinkovino golimumab.
In the second study, around 50% of patients receiving maintenance treatment with Simponi 100 mg and around 47% of those given Simponi 50 mg responded to treatment after 54 weeks, compared with around 31% of patients given placebo. 
V drugi študiji se je na zdravljenje po 54 tednih odzvalo približno 50 % bolnikov, ki so prejemali vzdrževalno zdravljenje z zdravilom Simponi v odmerku 100 mg, in okrog 47 % tistih, ki so prejemali 50-miligramski odmerek zdravila Simponi, v primerjavi s približno 31 % bolnikov, ki so prejemali placebo.
For the full list of side effects reported with Simponi, see the package leaflet. 
Za celoten seznam vseh neželenih učinkov, o katerih so poročali pri uporabi zdravila Simponi, glejte navodilo za uporabo.
In the third study, in patients who had not been previously treated with either methotrexate or another anti-TNF-α, after 24 weeks, 40% of patients (64 out of 159) who received Simponi with methotrexate achieved 50% reductions compared with 29% of patients (47 out of 160) who received placebo and methotrexate. 
V tretji študiji se je po 24 tednih pojavilo 50-odstotno zmanjšanje simptomov pri 40 % (64 od 159) bolnikov, ki predhodno še niso bili zdravljeni z metotreksatom ali drugim zaviralcem TNF- ter so prejemali zdravilo Simponi skupaj z metotreksatom, v primerjavi z 29 % (47 od 160) bolnikov, ki so prejemali placebo in metotreksat.
For ankylosing spondylitis, Simponi was compared with placebo over 24 weeks in one main study involving 356 patients who had not responded adequately to other treatments. 
Pri ankilozirajočem spondilitisu so zdravilo Simponi 24 tednov primerjali s placebom v eni glavni študiji, v katero je bilo vključenih 356 bolnikov, pri katerih je bil odziv na druga zdravljenja neustrezen.
For ulcerative colitis, Simponi was compared with placebo in two main studies in patients who had not responded to or could not use other treatments. 
Pri ulceroznemu kolitisu so zdravilo Simponi primerjali s placebom v dveh glavnih študijah pri bolnikih, ki se niso odzvali na druga zdravljenja ali za katere druga zdravljenja niso primerna.
For psoriatic arthritis, Simponi was compared with placebo over 24 weeks in one main study involving 405 patients who had not responded adequately to other treatments. 
Pri psoriatičnem artritisu so zdravilo Simponi 24 tednov primerjali s placebom v eni glavni študiji, v katero je bilo vključenih 405 bolnikov, pri katerih je bil odziv na druga zdravljenja neustrezen.
In the second study, after 14 weeks, 35% of patients who received Simponi alone (54 out of 153) achieved 20% reductions in the number and severity of symptoms compared with 18% of patients who received placebo (28 out of 155). 
V drugi študiji je po 14 tednih prišlo do 20-odstotnega zmanjšanja števila in resnosti simptomov pri 35 % (54 od 153) bolnikov, ki so prejemali zdravilo Simponi kot samostojno zdravilo, v primerjavi z 18 % (28 od 155) bolnikov, ki so prejemali placebo.
Of the patients who received Simponi, 59% (82 out of 138) had 20% reductions in the number and severity of symptoms after 14 weeks, compared with 22% of patients who were given placebo (17 out of 78). 
Pri bolnikih, ki so jemali zdravilo Simponi, je po 14 tednih prišlo do 20-odstotnega zmanjšanja števila in resnosti simptomov pri 59% (82 od 138 bolnikov) v primerjavi z 22% (17 od 78) bolnikov, ki so jemali placebo.
Of the patients who received Simponi, 51% (74 out of 146) had 20% reductions in the number and severity of symptoms after 14 weeks, compared with 9% of patients who were given placebo (10 out of 113). 
Pri bolnikih, ki so jemali zdravilo Simponi, je po 14 tednih prišlo do 20-odstotnega zmanjšanja števila in resnosti simptomov pri 51 % (74 od 146 bolnikov) v primerjavi z 9 % (10 od 113) bolnikov, ki so jemali placebo.
Of the patients who received Simponi, 71% (69 out of 97) had 20% reductions in the number and severity of symptoms after 16 weeks, compared with 40% of patients who were given placebo (40 out of 100). 
Pri bolnikih, ki so jemali zdravilo Simponi, je po 16 tednih prišlo do 20-odstotnega zmanjšanja števila in resnosti simptomov pri 71 % (69 od 97 bolnikov) v primerjavi s 40 % (40 od 100) bolnikov, ki so jemali placebo.
The European Commission granted a marketing authorisation valid throughout the European Union for Xeplion on 4 March 2011. 
Evropska komisija je dovoljenje za promet z zdravilom Xeplion, veljavno po vsej Evropski uniji, odobrila dne 4. marca 2011.
It is available as a prolongedrelease suspension for injection in pre-filled syringes (25, 50, 75, 100 and 150 mg). 
Na voljo je kot suspenzija za injiciranje s podaljšanim sproščanjem v predhodno napolnjenih injekcijskih brizgah (25, 50, 75, 100 in 150 mg).
The full EPAR for Xeplion can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Xeplion je na voljo na spletni strani agencije ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
In the brain, it attaches to several different receptors on the surface of nerve cells. 
V možganih se veže na različne receptorje na površini živčnih celic.
This is a summary of the European public assessment report (EPAR) for Xeplion. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Xeplion.
The main measure of effectiveness in the studies was the change in the patients' symptoms after nine or 13 weeks assessed using a standard scale for schizophrenia. 
Glavno merilo učinkovitosti v študijah je bila sprememba bolnikovih simptomov po devetih ali 13 tednih zdravljenja, ocenjena z uporabo standardne ocenjevalne lestvice za shizofrenijo
Because the medicine is a prolonged release suspension, it also has the advantage of being given at monthly intervals. 
Ker je zdravilo v obliki suspenzije s podaljšanim sproščanjem, je njegova prednost tudi jemanje v mesečnih presledkih.
The most frequently reported side effects are insomnia (difficulty sleeping), headache, anxiety, upper respiratory tract infection (colds), reactions at the site of injection, parkinsonism (neurological symptoms including tremor and impaired muscular control), increased weight, akathisia (restlessness), agitation, somnolence (sleepiness), nausea, constipation, dizziness, muscle and bone pain, tachycardia (rapid heartbeat), tremor (shaking), abdominal pain (stomach ache), vomiting diarrhoea, fatigue (tiredness) and dystonia (involuntary muscle contractions). 
Neželeni učinki, o katerih so najpogosteje poročali, so nespečnost, glavobol, anksioznost, okužbe zgornjih dihalnih poti (prehladi), reakcije na mestu injiciranja, parkinsonizem (nevrološki simptomi, vključno s tresavico in slabšim nadzorom nad mišicami), povečana telesna masa, akatizija (nemirnost), vznemirjenost, zaspanost, slabost, zaprtje, omotica, bolečine v mišicah in kosteh, tahikardija (zvišan srčni utrip), tresavica, bolečine v trebuhu, bruhanje, driska, utrujenost in distonija (nehoteni mišični krči).
What benefit has Xeplion shown during the studies? 
Kakšne koristi je zdravilo Xeplion izkazalo med študijami?
In two other studies (one long- and one short-term), Xeplion was not proven to be as effective as risperidone. 
Pri dveh drugih študijah (eni dolgoročni in ena kratkoročni) se zdravilo Xeplion ni izkazalo tako učinkovito kot risperidon.
This study looked at how well Xeplion prevented the relapse of severe symptoms. 
V tej študiji so proučevali, kako dobro zdravilo Xeplion preprečuje ponovitev hudih simptomov.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Xeplion. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Xeplion, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
The injections on days 1 and 8 are into the upper part of the shoulder (deltoid muscle), while the maintenance doses can be given in the buttocks or the deltoid muscle. 
Injekciji na prvi in osmi dan se injicirata v zgornji del ramena (deltoidno mišico), medtem ko se lahko vzdrževalni odmerki injicirajo v zadnjico ali deltoidno mišico.
The Committee decided that Xeplion's benefits are greater than its risks and recommended that it be given marketing authorisation. 
Odbor je zaključil, da so koristi zdravila Xeplion večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
Six short-term studies were carried out with Xeplion. 
Z zdravilom Xeplion je bilo izvedenih šest kratkoročnih študij.
What is the risk associated with Xeplion? 
Kakšna tveganja so povezana z zdravilom Xeplion?
Because paliperidone has already been authorised in the EU as Invega, the company used some of the data from Invega to support the use of Xeplion. 
Ker je paliperidon že odobren v EU kot zdravilo Invega, je družba v podporo uporabi zdravila Xeplion uporabila nekatere podatke o zdravilu Invega.
Other information about Xeplion 
Druge informacije o zdravilu Xeplion:
For more information on the use of Xeplion including how to adjust the doses, see the summary of product characteristics (also part of the EPAR). 
Za več informacij o uporabi zdravila Xeplion, vključno s prilagoditvijo odmerkov, glejte povzetek glavnih značilnosti zdravila (ki je prav tako del EPAR).
Schizophrenia is a mental illness that has a number of symptoms, including disorganised thinking and speech, hallucinations (hearing or seeing things that are not there), suspiciousness and delusions (false beliefs). 
Shizofrenija je duševna bolezen s številnimi simptomi, ki vključujejo neorganizirano mišljenje in govor, halucinacije (bolnik ima privide in prisluhe), sumničavost ter blodnje (zmotna prepričanja).
Xeplion treatment starts with two injections, one week apart, to bring the blood levels of paliperidone up, followed by monthly maintenance injections. 
Zdravljenje z zdravilom Xeplion se prične z dvema injekcijama v presledku enega tedna, da se raven paliperidona v krvi dvigne, temu pa sledijo mesečne vzdrževalne injekcije.
The CHMP noted that the studies comparing Xeplion with placebo and risperidone showed that the medicine is beneficial to patients with schizophrenia. 
CHMP je menil, da so študije, v katerih so primerjali zdravilo Xeplion s placebom in risperidonom, pokazale, da je zdravilo koristno za bolnike s shizofrenijo.
Two long-term studies lasting about a year were carried out with Xeplion. 
Z zdravilom Xeplion sta bili izvedeni tudi dve dolgoročni študiji, ki sta trajali približno eno leto.
Paliperidone acts mainly by blocking receptors for the neurotransmitters dopamine and 5-hydroxytryptamine (also called serotonin), which are involved in schizophrenia. 
Paliperidon v glavnem zavira receptorje za živčna prenašalca dopamin in 5-hidroksitriptamin (imenovan tudi serotonin), ki sodelujeta pri shizofreniji.
This allows for the injection to have a long duration of action. 
To omogoča dolgotrajno delovanje zdravila.
For more information about treatment with Xeplion, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Xeplion preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
In Xeplion, paliperidone has been attached to a fatty acid that allows it to be released slowly after being injected. 
V zdravilu Xeplion je paliperidon vezan na maščobno kislino, ki omogoča njegovo počasno sproščanje po vbrizganju.
Paliperidone has been authorised in the European Union as Invega since 2007 as an oral treatment for schizophrenia. 
Paliperidon je v Evropski uniji odobren od leta 2007 kot zdravilo Invega, peroralno zdravilo za shizofrenijo.
Why has Xeplion been approved? 
Zakaj je bilo zdravilo Xeplion odobreno?
In four short-term studies the reductions in symptom scores were greater for patients receiving Xeplion than for those receiving placebo. 
Pri štirih kratkoročnih študijah so bili rezultati zmanjšanja simptomov pri bolnikih, ki so prejemali zdravilo Xeplion, boljši kot pri bolnikih, ki so prejemali placebo.
Paliperidone is an active breakdown product (metabolite) of risperidone, another antipsychotic medicine that has been used in the treatment of schizophrenia since the 1990s. 
Paliperidon je aktivni presnovek (metabolit) risperidona, drugega antipsihotika, ki se za zdravljenje shizofrenije uporablja od devetdesetih let prejšnjega stoletja.
Xeplion must not be given to people who are hypersensitive (allergic) to paliperidone or any of the other ingredients, or to risperidone. 
Zdravila Xeplion ne smejo jemati bolniki, ki so preobčutljivi za (alergični na) paliperidon ali katero koli drugo sestavino zdravila ali risperidon.
Xeplion is used for the maintenance treatment of schizophrenia in adults whose disease has already been stabilised on treatment with paliperidone or risperidone. 
Zdravilo Xeplion se uporablja za vzdrževalno zdravljenje shizofrenije pri odraslih, pri katerih je bila bolezen stabilizirana med zdravljenjem s paliperidonom ali risperidonom.
(day 1) followed by 100 mg on day 8. 
Začetni injekciji znašata 150 mg na prvi dan zdravljenja (1. dan) in 100 mg na osmi dan (8. dan).
Some patients whose symptoms have not yet been stabilised may still be given Xeplion if they have responded well to oral paliperidone or risperidone in the past, their symptoms are mild to moderate and a long-acting injectable treatment is needed. 
Zdravilo se lahko uporablja tudi pri določenih bolnikih s shizofrenijo, ki še niso bili stabilizirani, a so se v preteklosti dobro odzvali na zdravljenje s peroralnim paliperidonom ali risperidonom, če so njihovi simptomi blagi do zmerni in je potrebno zdravljenje z dolgo delujočim zdravilom.
The dose may be adjusted depending on the medicine's benefit to the patient and how the patient tolerates the treatment. 
Mesečni vzdrževalni odmerek znaša 75 mg. Odmerek se lahko prilagodi glede na koristi zdravila pri posameznem bolniku in glede na to, kako bolnik prenaša zdravljenje.
The active substance in Xeplion, paliperidone, is an antipsychotic medicine. 
Zdravilna učinkovina zdravila Xeplion, paliperidon, je antipsihotično zdravilo.
For the full list of all side effects reported with Xeplion, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Xeplion, glejte navodilo za uporabo.
Xeplion is a medicine that contains the active substance paliperidone. 
Xeplion je zdravilo, ki vsebuje zdravilno učinkovino paliperidon.
The second study, involving 749 adults, compared Xeplion with risperidone long-acting injection (taken with oral risperidone supplements) and looked at the change in the patients' symptoms. 
V drugi študiji, v kateri je sodelovalo 749 odraslih bolnikov, so zdravilo Xeplion primerjali z dolgo delujočo injekcijo risperidona (ki se jemlje s peroralnimi dodatki risperidona) in ugotavljali spremembe simptomov pri bolnikih.
Xeplion was more effective than placebo in reducing schizophrenia symptoms in the short-term. 
Zdravilo Xeplion je bilo pri kratkoročnem izboljšanju simptomov shizofrenije učinkovitejše od placeba.
Prolonged-release means that the active substance is released slowly over a few weeks after being injected. 
Podaljšano sproščanje pomeni, da se zdravilna učinkovina po injiciranju sprošča več tednov.
Xeplion was also shown to be effective in preventing relapses in the longterm, with fewer patients in the Xeplion group having a relapse compared with the placebo group. 
Zdravilo Xeplion se je kot učinkovito izkazalo tudi pri dolgoročnem preprečevanju ponovitev, saj so se ponovitve pojavile pri manjšem številu bolnikov v skupini, ki je prejemala zdravilo Xeplion, v primerjavi s skupino, ki je prejemala placebo.
Two studies, involving 1,178 patients, compared Xeplion with risperidone long-acting injection (taken with oral risperidone supplements). 
V dveh študijah, v katerih je sodelovalo 1 178 bolnikov, so primerjali zdravilo Xeplion z dolgo delujočo injekcijo risperidona (ki se jemlje s peroralnimi dodatki risperidona).
One of the studies, involving 410 adults, compared Xeplion with placebo. 
V eni študiji, v kateri je sodelovalo 410 bolnikov, so zdravilo Xeplion primerjali s placebom.
What is Xeplion used for? 
Za kaj se zdravilo Xeplion uporablja?